Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00258388 · ClinicalTrials.gov registry record · Phase 2
Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
A Phase 2 study of Prostate Cancer, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 13
- Study locations
NCT00258388 is a Phase 2 study of Prostate Cancer that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 82 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The trial reports 13 study locations across 2 states.
The verdict
NCT00258388, a Phase 2 study of Prostate Cancer, has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 13
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. OGX-011 may help docetaxel and prednisone kill more tumor cells by making tumor cells less resistant to the drugs. PURPOSE: This randomized phase II trial is studying how well giving docetaxel and prednisone with or without OGX-011 works in treating patients with recurrent or metastatic prostate cancer that did not respond to previous hormone therapy.
Conditions Studied
Interventions
- DRUG prednisone
- DRUG docetaxel
- DRUG custirsen sodium
Study Locations (13)
Other
- Tom Baker Cancer Centre - Calgary
- Cross Cancer Institute - Edmonton
- QEII Health Sciences Center - Halifax
- Juravinski Cancer Centre at Hamilton Health Sciences - Hamilton
- BCCA - Cancer Centre for the Southern Interior - Kelowna
- London Regional Cancer Program - London
- CHUM - Hopital Notre-Dame - Montreal
- Atlantic Health Sciences Corporation - Saint John
- Odette Cancer Centre - Toronto
- Univ. Health Network-Princess Margaret Hospital - Toronto
- BCCA - Vancouver Cancer Centre - Vancouver
- CancerCare Manitoba - Winnipeg
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2005-09-28 |
| Est. Completion | 2011-01-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00258388
The ClinicalTrials.gov registry entry for NCT00258388 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The listed sponsor is NCIC Clinical Trials Group, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which prednisone is the first listed.
NCT00258388 reports 13 study locations spanning 2 distinct geographic areas - top geographies include Other, Washington.
Frequently Asked Questions
What is clinical trial NCT00258388 about?
NCT00258388 is a clinical study titled "Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy". RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. OGX-011 may help docetaxel and prednisone kill more tumor cells by making tumor cells less resistant to th...
What is the current status of trial NCT00258388?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2005-09-28. Estimated completion is 2011-01-18.
What conditions does trial NCT00258388 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00258388?
The interventions under investigation include: prednisone (DRUG), docetaxel (DRUG), custirsen sodium (DRUG).
Who is sponsoring clinical trial NCT00258388?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00258388 being conducted?
This trial has 13 study locations across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.